Research Paper Volume 13, Issue 15 pp 19272—19281

lncRNA ANRIL aggravates the chemoresistance of pancreatic cancer cells to gemcitabine by targeting inhibition of miR-181a and targeting HMGB1-induced autophagy


Figure 2. Knockdown of ANRIL inhibits the progression of pancreatic cancer. (A) Knockdown of ANRIL effectively inhibited ANRIL expression in PANC-1 cells and BxPC-3 cells. (B) MTT assay showed that the proliferation effect of pancreatic cancer cells transfected with si-ANRIL was significantly lower than that of the control group, while miR-181a inhibitor reversed the effect of si-ANRIL on pancreatic cancer cells. (C) Top: The transwell experiment reflected the effects of si-ANRIL and miR-181a inhibitor on the invasion ability of PANC-1 cells and BxPC-3 cells. Bottom: Western blot analyzed the expression levels of N-cadherin, E-cadherin, Vimentin, and Snail-1, they also represented the invasion ability of PANC-1 cells and BxPC-3 cells. (D) Scratch experiments revealed changes in healing ability of PANC-1 cells and BxPC-3 cells transfected with si-ANRIL, si-ANRIL+ miR-NC, si-ANRIL+miR-181a inhibitor, respectively. (E) The expression levels of LC3 I/II and Beclin1 reflected the regulation of autophagy levels of PANC-1 cells and BxPC-3 cells by si-ANRIL and miR-181a inhibitor. Standardized data with GAPDH. *P < 0.05, **P < 0.01, ***P < 0.001: si-NC, control siRNA; miR-NC, miRNA inhibitor control.